Overview

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Status:
Terminated
Trial end date:
2020-04-24
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the efficacy, safety and pharmacokinetics of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler versus placebo in adolescents and adult patients with cystic fibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim